Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.81 |
| ▸ | METAP2 | P50579 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1139356 | 0.92 | ACLY (0.78) | ACLYMETAP2 | |
| SCHEMBL9164473 | 0.91 | METAP2 (0.85) | ACLYMETAP2 | |
| Hydrochloric Acid SCHEMBL7409073 | 0.90 | METAP2 (0.82) | ACLYMETAP2 | |
| SCHEMBL21931105 | 0.89 | ACLY (1.00) | ACLYMETAP2 | |
| SCHEMBL5925257 | 0.88 | METAP2 (1.00) | ACLYMETAP2ALDH1A1 | |
| SCHEMBL491833 | 0.88 | METAP2 (1.00) | ACLYMETAP2ALDH1A1 | |
| SCHEMBL492000 | 0.88 | ACLY (0.72) | ACLYMETAP2 | |
| SCHEMBL10249221 | 0.88 | ACLY (0.67) | ACLYMETAP2ALDH1A1 | |
| SCHEMBL1093574 | 0.88 | CCR9 (0.70) | ACLYMETAP2 | |
| SCHEMBL491592 | 0.88 | ACLY (0.62) | ACLYMETAP2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-5132314-A | For administration to mammals, anthranilic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-07-21 | — | — | US | claimed |
| US-5081125-A | Substituted anthranilic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-01-14 | — | — | US | claimed |
| JP-3123773-A | — | — | None | — | — | JP | disclosed |
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| CN-101815514-B | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI AVENTIS DEUTSCHLAND | 2012-05-09 | — | — | CN | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| CN-1308606-A | Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICALS AG (DE) | 2001-08-15 | — | — | CN | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
| US-5132314-A | For administration to mammals, anthranilic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-07-21 | — | — | US | disclosed |
| US-5081125-A | Substituted anthranilic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| US-5077300-A | Parasiticides | CIBA-GEIGY CORPORATION (US) | 1991-12-31 | — | — | US | disclosed |
| JP-H03123773-A | ANTHELMINTIC | CIBA GEIGY AG | 1991-05-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | ACLY 705/4885METAP2 2482/4885ALDH1A1 457/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | ACLY 3602/4885METAP2 1707/4885ALDH1A1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.